Fortis Healthcare share news, announcements and annual reports

NSE: FORTISBSE: 532843Healthcare ServicesMid Cap

Fortis Healthcare Limited · Formerly Fortis Healthcare (India) · Face value ₹10 · Listed May 2007

₹761.50₹6.65 (0.87%)BSE ₹760.00

Share price at the NSE close on 2 Nov 2026. Previous close ₹768.15.

2 Nov: open ₹768.15, high ₹772.65, low ₹754.65

52-week range of traded prices to 2 Nov 2026

₹704.95Low, 23 Oct 2026₹1,040.50High, 3 Nov 2025

Next results date: the board meets on 5 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar

Market cap: ₹57,490 Cr156th largest listed
P/E: 54.86
P/B: 5.81
Dividend yield: 0.13%
ROE: 11.1%
ROCE: 12.7%
Debt to equity: 0.28
Volume, NSE: 13,12,28850.7% delivered

Fortis Healthcare share news and announcements

1,301 announcements, routine notices left out, newest first. Page 15 of 27.

Mar 2018
- 19 Mar · Management
  Resignation of Mr P S Joshi as Non- Executive Independent Director of the company w.e.f. March 19, 2018.
- 14 Mar · Legal
  Exchange has sought clarification from Fortis Healthcare Limited with respect to recent news item captioned "IHH to make Open Offer for Fortis". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Fortis Healthcare Limited has submitted their response.(Revised)
- 14 Mar · News Verification
  Exchange has sought clarification from Fortis Healthcare Limited with respect to recent news item captioned "IHH to make Open Offer for Fortis". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Fortis Healthcare Limited has submitted their response.
- 14 Mar · News Verification
  Exchange has sought clarification from Fortis Healthcare Limited with respect to recent news item captioned "IHH to make Open Offer for Fortis". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
- 8 Mar · Management
  Resignation of Ms Joji Sekhon Gill as Non- Executive Independent Director of the company w.e.f. March 07, 2018.
- 7 Mar · Rating
  Credit Rating Disclosure under Regulation 30- Intimation on revision in Credit Rating(s)With reference to the provisions of the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, it is hereby informed that there has been a change in the credit ratings by ICRA Limited and CARE Ratings of the Company and following subsidiaries- M/s. Escorts Heart Institute and Research Centre Limited, M/s. Fortis Hospitals Limited and M/s. Hiranandani Healthcare Private Limited.The report(s), from ICRA and CARE covering the rationale for revisions in credit ratings, are attached herewith.It is further informed that ICRA has withdrawn the long-term rating of [ICRA]A-(SO) for Rs. 10.31 crore term loan of one of the subsidiaries of the Company- M/s. Fortis C-Doc Healthcare Limited in accordance with ICRA's policy based on the no-objection certificate provided by the bankers. We will keep the stock exchanges informed about any further updates in this regard.This is for your information and records please.
- 3 Mar · Updates
  Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received a Notice (Ref. No. SFIO/INV/669/2018/13060(7)) under Section 217(1)(a) of Companies Act, 1956, on March 3, 2018 from Serious Fraud Investigation Office, Ministry of Corporate Affairs, New Delhi, seeking certain information and documents as mentioned therein to be submitted by March 9, 2018. The Company is in process of collating the said information and will be sharing the same in due course. The financial implication/ compensation/penalty and quantum of claims has not been referred in the aforesaid letter and hence cannot be ascertained.We will keep the stock exchanges informed about any further updates in this regard.This is for your information and records please.
- 1 Mar · Business
  Revised press release dated March 01, 2018, titled "Update Outcome of Board Meeting dated February 28, 2018".
- 1 Mar · Results
  Financial results for the period ended December 31, 2017.
- 1 Mar · Results
  Financial results for the period ended September 30, 2017.
- 1 Mar · Board meeting
  Outcome of Board Meeting held on February 28, 2018.This is to inform you that the Board of Directors of the Company at its meeting held today, inter-alia, considered and approved the Un-Audited Financial Results and Limited Review Report of the Company for the quarter(s) and period ended on September 30, 2017 and December 31, 2017.Copy of the Un audited Financial Results, Limited Review Report and press release being issued in this regard is attached for your reference and records. The Board Meeting commenced at 10:00 p.m. and concluded at 11:45 p.m.This is for your information and records please.
- 1 Mar · Board meeting
  Outcome of Board Meeting held on February 28, 2018.This is to inform you that the Board of Directors of the Company at its meeting held today, inter-alia, considered and approved the Un-Audited Financial Results and Limited Review Report of the Company for the quarter(s) and period ended on September 30, 2017 and December 31, 2017.Copy of the Un audited Financial Results, Limited Review Report and press release being issued in this regard is attached for your reference and records. The Board Meeting commenced at 10:00 p.m. and concluded at 11:45 p.m.This is for your information and records please.
Feb 2018
- 27 Feb · Legal
  Exchange had sought clarification from the Company with respect to news item captioned "Delhi HC orders seizure of Singh brothers assets". The response from the Company is enclosed.
- 27 Feb · Legal
  Exchange has sought clarification from the Company with respect to news item captioned "Delhi HC orders seizure of Singh brothers assets. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited
- 26 Feb · Updates
  With reference to our previous disclosure made vide letter reference no. FHL/SEC/STEX/RR/2017-18 dated February 23, 2018, wherein, it was informed that the Long Stop Date of the Memorandum of Understanding entered into between Fortis Cancer Care Limited ( FCCL), Lalitha Healthcare Private Limited ( LHPL), step down subsidiary(s) of the Company, Dr. Lakshmi Narayana Raju, Ms. Lakshmi Priya, Mr. S. Venkataramana Raju (collectively the Promoters of LHPL) and Anikrish Hospitals Private Limited, for, inter alia, sale of the entire shareholding held by FCCL to the Promoters of LHPL ( Proposed Transaction) has been extended till August 16, 2018.It is hereby informed that inadvertently, there is a typographical error in the said disclosure. The date of the initial disclosure sent in this regard was dated August 18, 2017 instead of August 18, 2018. The error is highly regretted.We will keep the stock exchanges informed about any further updates in this regard.This is for your information and records please.
- 23 Feb · Updates
  In continuation to our letter dated August 18, 2018, vide which it was informed that Fortis Cancer Care Limited ( FCCL), a step down subsidiary of the Company had entered into a memorandum of understanding ( MoU) with Lalitha Healthcare Private Limited ( LHPL), another step down subsidiary of the Company, Dr. Lakshmi Narayana Raju, Ms. Lakshmi Priya, Mr. S. Venkataramana Raju (collectively the Promoters of LHPL) and Anikrish Hospitals Private Limited, for, inter alia, sale of the entire shareholding held by FCCL, representing 79.43% of the total issued and paid up equity share capital of LHPL, to the Promoters of LHPL ( Proposed Transaction). It is hereby informed that the Parties to the MOU had yesterday agreed, to extend the Long Stop Date with effect from February 17, 2018 for 6 (Six) Months i.e. till August 16, 2018.
- 22 Feb · Updates
  Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received a Notice (Ref. No. TS/206/2013/45933/1529) under Section 206(1) of Companies Act, 2013, on February 21, 2018 from Registrar of Companies, Punjab & Chandigarh, seeking certain information and documents as mentioned therein to be submitted by March 3, 2018. The Company is in process of collating the said information and will be sharing the same in due course. The financial implication/ compensation/penalty and quantum of claims has not been referred in the aforesaid letter and hence cannot be ascertained.
- 19 Feb · Legal
  Exchange had sought clarification from the Company with respect to news item captioned "SFIO probe against Fortis and Religare". The response from the Company is enclosed
- 19 Feb · Legal
  Exchange has sought clarification from the Company with respect to news item captioned "SFIO probe against Fortis and Religare" In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
- 17 Feb · Updates
  Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received a communication from Securities and Exchange Board of India (SEBI) vide Ref. No. SEBI/HO/IVD/ID2/PS/CMR/FHL/5288/1/2018 dated February 16, 2018, confirming that an investigation has been instituted by SEBI in the matter of FORTIS HEALTHCARE LIMITED. Vide aforesaid letter, SEBI has asked to furnish information and documents as mentioned therein by February 26, 2018. The Company is in process of collating the said information and will be sharing the same with SEBI in due course. The financial implication/ compensation/penalty and quantum of claims has not been referred in the aforesaid letter and hence cannot be ascertained.We will keep the stock exchanges informed about any further updates in this regard.
- 15 Feb · Updates
  This is in continuation to our letter(s) Ref. No. FHL/SEC/STEX/RR/2017-18 dated August 11, 2017 and August, 31, 2017, whereby the Company had informed that, in the matter relating to M/s Daiichi Sankyo Company Limited v/s Oscar Investments Limited & Others, the Hon'ble Supreme Court of India had directed to maintain status quo with regards to the holding of Fortis Healthcare Holding Private Limited (FHHPL), a Promoter Group Entity, in the Company for both the encumbered and unencumbered shares.It is hereby informed that in the said matter the Hon'ble Supreme Court of India has today clarified that the direction to maintain status quo shall not apply to shares of the Company held by FHHPL as may have been encumbered on or before the interim orders dated August 11, 2017 and August, 31, 2017.Please find attached herewith the order passed by the Hon'ble Supreme Court of India dated today.We will keep the stock exchanges informed about any further updates in this regard.This letter may kindly be read in conjunction with the compliance under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 14 Feb · Rating
  Credit Rating
- 14 Feb · Board meeting
  Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held February 13, 2018, To, inter-alia, consider and approve the Un-Audited Financial Results for the quarter and Half Year ended September 30, 2017 and for the quarter and Period ended December 31, 2017. The Company has now informed the Exchange that the meeting of the Board of Directors has now been Scheduled to be held on February 28, 2018, for approval of the un-audited financial results for the Quarters ended September 30, 2017 and December 31, 2017.
- 13 Feb · Board meeting
  Outcome of Board Meeting held on February 13, 2018.This is to inform you that in continuation to our letter Ref. No. FHL/SEC/STEX/RR/2017-18 dated February 8, 2018, the Board of Directors of Fortis Healthcare today accepted the resignations of Mr Malvinder Mohan Singh, Executive Chairman and Dr Shivinder Mohan Singh, Non-Executive Vice Chairman with effect from February 8, 2018. The board acknowledged and placed on record their support and contribution in making Fortis a par excellence healthcare delivery service provider. The Board, as an interim measure, has constituted a Management Committee to oversee the functioning of the Company from a strategic and operational guidance perspective and vested with the Management Committee all the responsibilities and authorities of Executive Chairman and Non-Executive Vice Chairman.Further, with reference to our letter Ref. No. FHL/SEC/STEX/RR/2017-18 dated February 12, 2018, vide which we requested the stock exchanges for extending the timelines for holding board meeting for approval of the un-audited financial results for the Quarters ended September 30, 2017 and December 31, 2017, it is hereby informed that for the reasons stated therein, the financial results could not be tabled and therefore the results were not considered and approved. The Board decided to hold the Board Meeting for approval of the financial results for the Quarters ended September 30, 2017 and December 31, 2017 on February 28, 2018.Accordingly, the trading window will continue to remain closed till March 2, 2018.The Board Meeting commenced at 1200 Noon and concluded at 1900 Hours.
- 13 Feb · Rating
  Credit RatingWith reference to the provisions of the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, it is hereby informed that there has been a change in the credit ratings by ICRA of the Company and of the following subsidiaries of the Company - M/s. Fortis Hospitals Limited, M/s. Escorts Heart Institute and Research Centre Limited, M/s. Hiranandani Healthcare Private Limited and M/s. Fortis C-Doc Healthcare Limited.The report(s), from the ICRA covering the rationale for revisions in credit ratings, are attached herewith.We will keep the stock exchanges informed about any further updates in this regard.This is for your information and records please.
- 13 Feb · Legal
  Exchange had sought clarification from Fortis Healthcare Limited with respect to announcement dated 13-Jan-2018, regarding "Disclosure under Regulation 30 and letter Ref. No. FHL/SEC/STEX/RR/2017-18 dated November 14, 2017 wherein the Company had informed about entering into a term sheet (Term Sheet) in relation to the proposed acquisition by the Company and/or its subsidiaries of the equity and financial securities, in the relevant Indian entities under RHT Health Trust (RHT) of, International Hospital Limited and Fortis Health Management Limited (and consequentially Escorts Heart and Super Speciality Hospital Limited, Hospitalia Eastern Private Limited and Fortis Hospotel Limited) from the wholly-owned subsidiaries of RHT (Proposed Transaction). As per the agreed Term Sheet, the parties had entered into an exclusivity period for 60 days, commencing from the date of the Term Sheet with a view to executing definitive agreements for the Proposed Transaction. The said period of 60 days expires on January 12, 2018. It is hereby further informed that, the parties to the Term Sheet have on January 12, 2018, mutually agreed to extend the Exclusivity Period by an additional period of 30 days from January 12, 2018. This is in order to facilitate the continued negotiations and finalisation of the Definitive Agreements in relation to the Proposed Transaction. The response of the Company is attached.
- 13 Feb · Business
  This is in continuation to our letter Ref. No. FHL/SEC/STEX/RR/2017-18 dated November 14, 2017, wherein the Company had informed about entering into a term sheet ("Term Sheet") in relation to the proposed acquisition by the Company and/or its subsidiaries of the equity and financial securities, in the relevant Indian entities under RHT Health Trust ("RHT") namely, International Hospital Limited and Fortis Health Management Limited (and consequentially Escorts Heart and Super Speciality Hospital Limited, Hospitalia Eastern Private Limited and Fortis Hospotel Limited) from the wholly-owned subsidiaries of RHT ("Proposed Transaction"), and letters dated January 13, 2018 and January 16, 2018 for extending the exclusivity period under the Term Sheet for a further period of 31 (thirty-one) days from January 12, 2018. It is hereby further informed that, the parties to the Term Sheet have entered into definitive agreement(s) with respect to the Proposed Transaction on February 12, 2018. The completion of the Proposed Transaction will be subject to the satisfaction of conditions precedent under the definitive agreement(s) including regulatory and shareholder approvals by the Company, approvals by RHT unit holders and other approvals as may be required. Further the Company has submitted a Copy of press release dated February 13, 2018, titled "Fortis Signs Definitive Agreements To Acquire the Entire Portfolio of Assets of RHT Health Trust (RHT), Listed in Singapore
- 12 Feb · Management
  Appointment of Mr Lt. Gen. Tejinder Singh Shergill as Non- Executive Independent Director of the company w.e.f. February 12, 2018.Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors have today, through circulation, approved, the appointment of Lt. Gen. Tejinder Singh Shergill (DIN: 00940392) as an Additional (Independent) Director with immediate effect for a period of five years, subject to the approval of the shareholders. Lt. General Tejinder Singh Shergill PVSM, graduated from the National Defence Academy, Khadakwasla, where he was awarded the President's Gold Medal. He was commissioned into The Deccan Horse and has over 40 years of experience in the military that included battle during the 1965 and 1971 Indo-Pak conflicts. He was Defence Attach at the Indian Embassy, Washington DC, USA; later he commanded a Division in Jammu and Kashmir, a Corps in the North-East, both during counter militancy and counter insurgency operations; also, he was Commandant of the Indian Military Academy. He is a former Chairman of the Punjab Public Service Commission.Currently he is Director and Advisor, University of Petroleum and Energy Studies and a practicing Graduate Life Coach of the International Coaching Federation, USA. He lectures frequently on Leadership, Motivation, Energy, Terrorism and Insurgency. He is author of the book Counter insurgency Support to a Host Nation, Lancer's Publications, 1987.Further, there is no inter-se relationship between the Directors.You are requested to take the same on records.
- 12 Feb · Updates
  Seeking Extension for approval of Financial Results for the Quarter ended September 30, 2017 and December 31, 2017
- 12 Feb · Legal
  Exchange has sought clarification from Fortis Healthcare Limited with respect to announcement dated 13-Jan-2018, regarding "Disclosure under Regulation 30 and letter Ref. No. FHL/SEC/STEX/RR/2017-18 dated November 14, 2017 wherein the Company had informed about entering into a term sheet ( Term Sheet) in relation to the proposed acquisition by the Company and/or its subsidiaries of the equity and financial securities, in the relevant Indian entities under RHT Health Trust (RHT) of, International Hospital Limited and Fortis Health Management Limited (and consequentially Escorts Heart and Super Speciality Hospital Limited, Hospitalia Eastern Private Limited and Fortis Hospotel Limited) from the wholly-owned subsidiaries of RHT ( Proposed Transaction). As per the agreed Term Sheet, the parties had entered into an exclusivity period for 60 days, commencing from the date of the Term Sheet with a view to executing definitive agreements for the Proposed Transaction. The said period of 60 days expires on January 12, 2018. It is hereby further informed that, the parties to the Term Sheet have on January 12, 2018, mutually agreed to extend the Exclusivity Period by an additional period of 30 days from January 12, 2018. This is in order to facilitate the continued negotiations and finalisation of the Definitive Agreements in relation to the Proposed Transaction. In this regard you are require to update on said proposed acquisition ASAP.The response of the Company is awaited.
- 9 Feb · News Verification
  Exchange has sought clarification from Fortis Healthcare Limited with respect to recent news item captioned "Manipal Hospitals, backed by TPG in advanced talks to merge Fortis Health with self". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Fortis Healthcare Limited has submitted their response.
- 9 Feb · Legal
  Exchange had sought clarification from the Company with respect to news item captioned " Looks like there is lack of Corporate Governance in Fotis, Deloitte refuses to certify Fortis Q2 results, Singh Brothers said to have taken out $78M from the Firm ". The response from the Company is enclosed.
- 9 Feb · News Verification
  Exchange has sought clarification from Fortis Healthcare Limited with respect to recent news item captioned "Manipal Hospitals, backed by TPG in advanced talks to merge Fortis Health with self". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
- 9 Feb · Legal
  Exchange has sought clarification from the Company with respect to news item captioned Looks like there is lack of Corporate Governance in Fortis, Deloitte refuses to certify Fortis Q2 results, Singh Brothers said to have taken out $78M from the Firm. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
- 8 Feb · Management
  Change in Director(s) of the company.Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Mr. Malvinder Mohan Singh, Executive Chairman (DIN: 00042981) and Dr. Shivinder Mohan Singh, Non-Executive Vice Chairman (DIN: 00042910) have tendered their resignation from the directorships of the Company. The resignation letter (copy attached) was circulated to the Board and the Board has decided to discuss the matter in detail at its meeting scheduled on February 13, 2018. You are requested to take the same on records.
- 8 Feb · Board meeting
  To, inter-alia, consider and approve the Un-Audited Financial Results for the quarter and Half Year ended September 30, 2017 and for the quarter and Period ended December 31, 2017.
- 2 Feb · Legal
  Exchange had sought clarification from the Company with respect to news item captioned "Daiichi wins Rs 3,500 crore arbitration case against Singh brothers in Delhi High Court". The response from the Company is enclosed.
Jan 2018
- 31 Jan · Updates
  This is with reference to your mail dated today and the recent news item which appeared in Economic Times titled Daiichi wins Rs 3,500 crore arbitration case against Singh brothers in Delhi High Court.In this regard, we would like to submit that the Company had vide its letter Ref. FHL/SEC/STEX/RR/2017-18 dated May 29, 2017 informed that stock exchanges about the sequence of the events relating to aforesaid matter. We confirm from media sources and publicly available documents at website of Hon ble High Court of Delhi that a verdict with regard to enforcement of arbitration award has been pronounced today.We confirm that the Company was not a party to the arbitration and/ or is not a party to ongoing proceedings in the Delhi High Court and as such is not involved or impacted by its outcome. We further confirm that the proceedings don't have any ad-interim or interim order passed against or in favor of the Company. Also, any outcome of the proceeding are reasonably expected to have no direct impact on the Company or its operations.We assure you that we will keep the stock exchanges updated/informed in terms of Regulation 30 of the SEBI (LODR) Regulations, 2015.This is for your kind information and records purposes.
- 31 Jan · Legal
  Exchange has sought clarification from the Company with respect to news item captioned "Daiichi wins Rs 3,500 crore arbitration case against Singh brothers in Delhi High Court " In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
- 16 Jan · Updates
  Dear Sir(s),With reference to our previous disclosure made vide letter reference no. FHL/SEC/STEX/RR/2017-18 dated January 13, 2018, wherein, it was informed that in relation to the proposed acquisition by the Company and/or its subsidiaries of the equity and financial securities, in the relevant Indian entities under RHT Health Trust, the parties to the Term Sheet have mutually agreed to extend the Exclusivity Period from January 12, 2018. This is in order to facilitate the continued negotiations and finalisation of the Definitive Agreements in relation to the Proposed Transaction.It is hereby informed that inadvertently, there is a typographical error in the said disclosure. The Exclusivity Period has been actually extended by 31 days instead of 30 days as mentioned in the last disclosure. Rest of the terms as mentioned in the disclosure remains the same.The error is highly regretted.We will keep the stock exchanges informed about any further updates in this regard.This letter may kindly be read in conjunction with the compliance under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.This is for your information and records please.
- 13 Jan · Updates
  'Disclosure under Regulation 30'.This is in continuation to our letter Ref. No. FHL/SEC/STEX/RR/2017-18 dated November 14, 2017 wherein the Company had informed about entering into a term sheet ( Term Sheet) in relation to the proposed acquisition by the Company and/or its subsidiaries of the equity and financial securities, in the relevant Indian entities under RHT Health Trust (RHT) of, International Hospital Limited and Fortis Health Management Limited (and consequentially Escorts Heart and Super Speciality Hospital Limited, Hospitalia Eastern Private Limited and Fortis Hospotel Limited) from the wholly-owned subsidiaries of RHT ( Proposed Transaction). As per the agreed Term Sheet, the parties had entered into an exclusivity period for 60 days, commencing from the date of the Term Sheet with a view to executing definitive agreements for the Proposed Transaction. The said period of 60 days expires on January 12, 2018.It is hereby further informed that, the parties to the Term Sheet have on January 12, 2018, mutually agreed to extend the Exclusivity Period by an additional period of 30 days from January 12, 2018. This is in order to facilitate the continued negotiations and finalisation of the Definitive Agreements in relation to the Proposed Transaction. We will keep the stock exchanges informed about any further updates in this regard.This letter may kindly be read in conjunction with the compliance under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.This is for your information and records please.
- 5 Jan · News Verification
  Exchange has sought clarification from Fortis Healthcare Limited with respect to recent news item captioned "Fortis Healthcare in talks with PE firm to sell stake". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Fortis Healthcare Limited has submitted their response.
- 5 Jan · News Verification
  Exchange has sought clarification from Fortis Healthcare Limited with respect to recent news item captioned "Fortis Healthcare in talks with PE firm to sell stake". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Dec 2017
- 15 Dec · Updates
  Update on Scheme
- 7 Dec · News Verification
  Exchange has sought clarification from Fortis Healthcare Limited with respect to recent news item captioned "Fortis faces 'criminal negligence' charges, may lose licence". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Fortis Healthcare Limited has submitted their response.
- 7 Dec · News Verification
  Exchange has sought clarification from Fortis Healthcare Limited with respect to recent news item captioned "Fortis faces 'criminal negligence' charges, may lose licence". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Nov 2017
Sep 2017
- 27 Sep · Meeting
  Copy Srutinizers report of Annual General Meeting held on September 26, 2017. Further, the company has informed the Exchange regarding voting results.

Fortis Healthcare share news and announcements

Mar 2018

Feb 2018

Jan 2018

Dec 2017

Nov 2017

Sep 2017